Evommune, Inc.(EVMN)

$12.36▼-0.60 (-4.63%)

Chart

Evommune, Inc.(EVMN)

NYSE

$12.36▼-0.60 (-4.63%)

Chart Studio

EVMN(EVMN)

EVMN

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.68

Aug 6, 2026 · Reports before open

Revenue Estimate

$1M

Analyst Sentiment

Wall St. Consensus

Buy

4 analysts·Low coverage

Score

2 Buy (50%)2 Hold (50%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

250%

Hold

250%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$26.00

+110.4%

Consensus

$42.00

+239.8%

Bull

$55.00

+345.0%

12-Month Target Range4 analysts

$26.00$42.00$55.00

Current $12.36Consensus

Current Price

$12.36

Upside to Consensus

$29.64

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-69.70%

EPS—

FY2028

Rev+60.00%

EPS—

FY2029

Rev+212.50%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$4M	$1M	$2M	$6M	$49M
Low	$4M	$1M	$2M	$6M	$49M
High	$4M	$1M	$2M	$6M	$49M
EBITDA Avg	$-4M	$-1M	$-2M	$-6M	$-49M
Low	$-4M	$-1M	$-2M	$-6M	$-49M
High	$-4M	$-1M	$-2M	$-6M	$-49M
EBIT Avg	$-4M	$-1M	$-2M	$-6M	$-49M
Low	$-4M	$-1M	$-2M	$-6M	$-49M
High	$-4M	$-1M	$-2M	$-6M	$-49M
Net Income Avg	$-105M	$-137M	$-104M	$-132M	$-118M
Low	$-111M	$-152M	$-119M	$-132M	$-118M
High	$-89M	$-60M	$-88M	$-132M	$-118M
EPS Avg	$-3.03	$-3.21	$-3.27	$-4.19	$-3.75
Low	$-3.53	$-4.81	$-3.79	$-4.19	$-3.75
High	$-2.82	$-1.91	$-2.79	$-4.19	$-3.75
Analysts (Rev / EPS)	5 / 7	5 / 7	5 / 4	2 / 2	2 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$500,000	$4M	—	—	—	—	—	—
Low	$500,000	$4M	—	—	—	—	—	—
High	$500,000	$4M	—	—	—	—	—	—
EBITDA Avg	$-500,000	$-4M	—	—	—	—	—	—
Low	$-500,000	$-4M	—	—	—	—	—	—
High	$-500,000	$-4M	—	—	—	—	—	—
EBIT Avg	$-500,000	$-4M	—	—	—	—	—	—
Low	$-500,000	$-4M	—	—	—	—	—	—
High	$-500,000	$-4M	—	—	—	—	—	—
Net Income Avg	$-25M	$-24M	$-25M	$-26M	$-27M	$-29M	$-26M	$-26M
Low	$-30M	$-24M	$-25M	$-26M	$-27M	$-29M	$-26M	$-26M
High	$-23M	$-24M	$-25M	$-26M	$-27M	$-29M	$-26M	$-26M
EPS Avg	$-0.73	$-0.72	$-0.73	$-0.77	$-0.81	$-0.85	$-0.78	$-0.78
Low	$-0.88	$-0.72	$-0.73	$-0.77	$-0.81	$-0.85	$-0.78	$-0.78
High	$-0.67	$-0.72	$-0.73	$-0.77	$-0.81	$-0.85	$-0.78	$-0.78
Analysts (Rev / EPS)	4 / 7	3 / 3	— / 3	— / 2	— / 2	— / 2	— / 3	— / 6

Earnings Surprises

Recent Analyst Actions

Jun 30, 2026Morgan Stanley

Evommune price target lowered to $26 from $55 at Morgan Stanley

Target:$26.00

+72.8%from $15.05

May 26, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Evommune Inc (EVMN)

Target:$50.00

+118.6%from $22.87

May 11, 2026Morgan Stanley

Evommune price target raised to $55 from $54 at Morgan Stanley

Target:$55.00

+124.5%from $24.50

Feb 18, 2026Morgan Stanley

Evommune price target raised to $54 from $36 at Morgan Stanley

Target:$54.00

+73.9%from $31.06

Feb 10, 2026Evercore ISI

Evommune price target raised to $55 from $40 at Evercore ISI

Target:$55.00

+82.7%from $30.10

Feb 10, 2026H.C. Wainwright

Evommune price target raised to $65 from $35 at H.C. Wainwright

Target:$65.00

+125.6%from $28.81

Jan 22, 2026Oppenheimer

Evommune initiated with an Outperform at Oppenheimer

Target:$42.00

+127.3%from $18.48

Jan 7, 2026Raymond James

Evommune initiated with a Strong Buy at Raymond James

Target:$40.00

+146.9%from $16.20

Jan 6, 2026H.C. Wainwright

Evommune initiated with a Buy at H.C. Wainwright

Target:$35.00

+127.7%from $15.37

Dec 1, 2025Leerink Partners

Evommune initiated with an Outperform at Leerink

Target:$42.00

+102.8%from $20.71

Dec 1, 2025Evercore ISI

Evommune initiated with an Outperform at Evercore ISI

Target:$40.00

+93.1%from $20.71

Dec 1, 2025Morgan Stanley

Evommune initiated with an Overweight at Morgan Stanley

Target:$36.00

+73.8%from $20.71

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance